ShareShareSharePrintMailGooglePinterestDiggRedditStumbleuponDeliciousBufferTumblr,Lauren Culp Lauren Culp is the Publisher & CEO at CUInsight.com.She leads the growing team at CUInsight, works with organizations serving credit unions to maximize their brand and exposure, connects … Web: https://www.cuinsight.com Details Welcome to the CUInsight Minute, sixty seconds from our Publisher & CEO Lauren Culp with the top three of our favorite things from the week.Mentioned this week:Educating emerging leaders is the future of credit unionsby JOHN PEMBROKE, CUESAt CUES, we believe that investing in the next generation of leaders is incredibly important to the credit union industry.This is why our mission includes educating and developing future leaders. (read more)Top 5 ways to improve collection performanceby JONATHAN BARKLEY, SWBCWhen it comes to collections, cutting costs while also improving performance may seem like a tall order—especially when the resources you have to dedicate to time, personnel, and technology are already spread too thin. (read more)Lessons from Dolittle: Five ways to grow long-term impact with a diverse teamby TANSLEY STEARNS, CANVAS CREDIT UNIONI love the movies. I relish great storytelling and suspending my disbelief to immerse in another world. Now that she’s getting a bit older, my daughter MacKenzie and I have created a joint hobby of finding films that we may both enjoy. (read more)
Dec 7, 2004 (CIDRAP News) – The federal government is buying 1.2 million doses of flu vaccine made in Germany to augment the strained US supply, the Department of Health and Human Services (HHS) announced today.HHS Secretary Tommy Thompson announced the purchase of the vaccine, made by GlaxoSmithKline, at a news teleconference. “We’ll have it available this month,” he said. “This will allow us to get more vaccine into the hands of those who need it most.”Because the vaccine is not licensed in the United States and licensing is a lengthy process, it will be used under “investigational new drug” (IND) rules, Thompson said. That means people will have to sign a consent form acknowledging their awareness of possible risks before getting a shot. But Thompson and Lester Crawford, acting commissioner of the Food and Drug Administration (FDA), said the vaccine is safe.The vaccine, called Fluarix, is used in 30 countries. The FDA reviewed GlaxoSmithKline’s manufacturing processes and inspected the plant that makes the vaccine before HHS decided to buy it, Thompson said.The consent form will explain “what the public should expect in terms of risk,” said Crawford. “What the public should know at this point is that the vaccine is not investigational because we have real questions about it, but because the company elected not to enter the US market last year, so they didn’t apply for approval.” He called the probability of safety problems with the vaccine “very low indeed.”Thompson said GlaxoSmithKline has agreed to supply up to 4 million doses to the US under IND rules, but he didn’t predict how many doses HHS might buy beyond the initial 1.2 million.The 1.2 million doses will increase the total US supply for this season to slightly more than 62 million doses, which includes about 58 million doses from Aventis Pasteur and 3 million doses of MedImmune’s FluMist, Thompson said.Thompson said the Centers for Disease Control and Prevention will distribute the GlaxoSmithKline vaccine doses where they are needed and will release a distribution plan in a few days. The company is charging HHS about $7 per dose, but there will be some additional costs for distribution, he said.GlaxoSmithKline said the IND rules provide that the vaccine can be given to people at least 3 years old who qualify for vaccination under the current US guidelines, which reserve the shots for people in high-risk groups.Another foreign firm viewed as a potential supplier of flu vaccine to the United States, Canada’s ID Biomedical, announced today that it must save its remaining doses for Canada, according to a Canadian Press (CP) report. HHS officials had previously said they were considering buying 1.2 million doses from the Vancouver, B.C., company.The company said it was selling the doses on the Canadian market at the request of the government, according to the CP report. The story said reports of the US vaccine shortage spurred an unusual Canadian demand for flu shots earlier this fall, sparking fears of a shortage in Canada.At the news conference, Crawford acknowledged the ID Biomedical announcement but said the FDA was still discussing the possibility of buying some vaccine from the company. The CP report said FDA officials spent a week inspecting the firm’s vaccine plant in Ste.-Foy, Que.Crawford also said that two companies have announced this week that they want to enter the US flu vaccine market, one as early as 2005 and the other by 2007. This year Aventis Pasteur and MedImmune are the only companies providing licensed flu vaccines in the US. California-based Chiron Corp. was to have supplied up to 48 million doses before contamination problems at the company’s plant in Liverpool, England, prompted British authorities to shut down the plant, triggering the American vaccine shortage.Crawford didn’t name the two companies planning to enter the market, but ID Biomedical yesterday announced a long-term agreement to sell flu vaccine to three US wholesalers, starting as early as next year, depending on licensing of the vaccine. The company said the agreement covers at least 8 years. The firm’s production capacity in 2005 will be about 22 million doses, officials said.GlaxoSmithKline, in a news release about the sale of doses to HHS, said it has “a long-term strategy” to seek FDA licensing of Fluarix.In other comments, Crawford said the FDA has been reviewing proposals by Illinois, New Mexico, and New York City to buy a total of 750,000 doses of non-US-licensed flu vaccine made abroad by Aventis. “By the end of the week we expect to have gotten through all of the information,” but he didn’t predict whether the FDA will approve the plans.
Published on September 18, 2018 at 4:21 pm Contact Billy: [email protected] | @Wheyen3 ACC play begins for Syracuse at Clemson on Thursday, Jan. 3. The home conference opener comes on Jan. 13 against North Carolina. The Orange play two conference opponents twice: Boston College and Pittsburgh.In its overall schedule, Syracuse will play 11 teams that made it to the NCAA tournament last year out of the 28 games on the schedule. The highlight game in nonconference play for the Orange will be at Oregon. The Ducks feature 2017-18 AP first-team All-American point guard Sabrina Ionescu.Syracuse will also take part in two holiday tournaments. Over Thanksgiving break, the Orange plays three games at the Cancun Challenge. And in the week leading up to Christmas, SU plays two games in St. Petersburg, Florida, at the St. Pete Classic.AdvertisementThis is placeholder textLast season, the Orange finished 22-9 overall, 10-6 in the ACC. SU returns the entirety of the starting lineup it used in every game: Tiana Mangakahia, Gabrielle Cooper, Miranda Drummond, Digna Strautmane and Amaya Finklea-Guity.The Orange also adds two five-star freshmen, Emily Engstler and Kadiatou Sissoko, according to the ESPN Hoopgurlz rankings. Maeva Djaldi-Tabdi, a five-star recruit from the 2017 class, will also be eligible to play after redshirting in her first year on campus.Here’s the full Syracuse schedule with conference matchups in bold.Tuesday, Nov. 6, 3 p.m. – vs. North DakotaSaturday, Nov. 10, 4 p.m. – at OregonSunday, Nov. 18, 2 p.m. – vs. BucknellThursday, Nov. 22, 1:30 p.m. – vs. Kansas State (in Cancun, Mexico)Friday, Nov. 23, 1:30 p.m. – vs. Princeton (in Cancun, Mexico)Saturday, Nov. 24, 1:30 p.m. – vs. DePaul (in Cancun, Mexico)Thursday, Nov. 29, 7 p.m. – at MinnesotaSunday, Dec. 2, 2 p.m. – vs. TowsonWednesday, Dec. 5, 7 p.m. – vs. Maryland Eastern ShoreMonday, Dec. 17, 11 a.m. – vs. NiagaraFriday, Dec. 21, 7:30 p.m. – vs. Duquesne (in St. Petersburg, Florida)Saturday, Dec. 22, 7:30 p.m. – vs. UCF (in St. Petersburg, Florida)Thursday, Jan. 3, 7 p.m. – at ClemsonSunday, Jan. 6, 2 p.m. – at Virginia TechSunday, Jan. 13, 3 p.m. – vs. North CarolinaThursday, Jan. 17, 7 p.m. – at PittsburghSunday, Jan. 20, 7 p.m. – at Georgia TechWednesday, Jan. 23, 7 p.m. – at MiamiSunday, Jan. 27, 1 p.m. – at DukeThursday, Jan. 31, 7 p.m. – vs. VirginiaThursday, Feb. 7, TBA – at LouisvilleSunday, Feb. 10, 2 p.m. – vs. Boston CollegeThursday, Feb. 14, 7 p.m. – vs. North Carolina StateSunday, Feb. 17, 2 p.m. – vs. Wake ForestThursday, Feb. 21, 7 p.m. – vs. PittsburghMonday, Feb. 25, 6 p.m. – vs. Notre DameThursday, Feb. 28, 7 p.m. – at Florida StateSunday, March 3, TBA – at Boston College Comments The Atlantic Coast Conference released its full women’s basketball schedule on Tuesday. Syracuse will play 16 ACC games beginning at the start of conference play on Jan. 3.The biggest name team to come to the Carrier Dome is defending national champion Notre Dame. The Orange host the Fighting Irish on Monday, Feb. 25. The game against UND is the culmination of a five-game homestand for SU. Facebook Twitter Google+
Asbury, Christopher19Wellington, Ks815 N Woodlawn #148 WellingtonWellington PDAgg. Battery, Agg. Assault, Criminal Threat and Disorderly Conduct6/13/13 Scott, Andre32Wichita, KSKansas Star CasinoKRGCManipulating gaming device6/15/13 Dossey, Tiana N45Mulvane, KS416 E. Bridge, Mulvane KSSUSOServing Sentence6/14/13 NameAgeHome TownLocation of ArrestAgencyChargesDate of Arr Reusch, Wesley Markus20Wellington, Ks1000 W 8th, Wellington KsWellington PDTheft of services6/15/13 Moor, Thomas53Mulvane, KS807 1/2 S College, Mulvane KsMulvane PDDV battery6/11/13 Monday 0800Â toÂ Monday 0800 Jones, Carl E.50Wichita, KS500 N. Washington, Wellington KsSUSOProbation Violation6/10/13 Johnson, Jason38Wellington, Ks817 W 8th, Wellington, KsWellington PDDriving while suspended6/10/13 Cady, Shawn31Wichita, KS610 E. Hillside, Wellington KsSUSOServing Sentence6/10/13 Baker, Timothy42Wichita, KS777 Kansas Star DriveMulvane PDPossession of Meth, Possession of Drug Paraphernalia6/12/13 Buffington, John K35Homeless200 N C Wellington KsWellington PDObstruction of Legal Process, Sedgwick County Warrant for P.V.6/12/13 Stover, Courtny22Wellington, Ks100 N Washington, Wellington KsWellington PDBattery6/15/13 WEEKLYÂ Â BOOKINGS06/10/2013 thru 06/17/2013 Young, Lana L.50Wellington, Ks1000 W. 8th Street, Wellington KsWellington PDD.U.I., T.O.C. and Refusal of B.A.T.6/12/13 Sanders, Jenny29Wellington, Ks610 E Hillside Wellington KsBondsmanFTA6/11/13 Franks, Starkell26Wichita, KS610 E Hillside Wellington KsSUSOServing Sentence6/11/13 Goings, Joseph32Columbus, KS1205 N C Wellington KSSUSOFalse Impersonation, Harass by Telecom device6/12/13 Hill, Kyle21Lake of Ozarks MO500 N Washington Wellington KSSUSOSg County warrant6/12/13 Herl, Shirley34Wellington, Ks2022 E 16th, Wellington KsWellington PDTheft6/14/13 Seaton, Floyd R29Wichita, KSSedgwick CountySedgwick SOFailure to Appear6/13/13 Shockley, Michael J28Wellington, Ks500 N. Washington, Wellington KsSUSOServing Sentence6/13/13 Church, Dale74Wellington, Ks913 E 12thSUSOProbation Violation and Harrassment by Telephone6/10/13 Hollis, Kenneth L50Belle Plaine, KS1625 E 60th Ave, Belle Plaine, KSSUSODV Battery, Criminal Threat6/12/13 Ribordy, McKenzie24Derby, KS433 E Blair Mulvane, KSMulvane PDDUI, no insurance6/14/13 Ryberg, Kathleen18Wellington, Ks1009 Shady Lane Ct, Wellington KsWellington PDDUI, No Insurance, Minor in Possession6/16/13 O’Neal, Brandon L.20Conway Springs Ks.610 E. Hillside, Wellington KsState Fire MarshallAggravated Arson6/12/13 Beltz, James23Belle Plaine, KS521 W 7th Belle PlaineBPPDCriminal Damage to Property (F), Criminal Damage to Property (M), Criminal Threat (WARRANT ARRESTS)6/10/13 Nance, Benjamin33Derby, KS101 S. Rock Rd., Derby, KSSUSOServing Sentence6/14/13 Daves, William33Wellington, Ks100 N Washington, Wellington KsWellington PDBattery6/15/13 Harlan, Sarah M30Mulvane, KS1520 Rockwood Mulvane, KSMulvane PDFailure to Appear6/13/13 The following are the Sumner County Sheriff jail bookings for June 10 to June 17, 2013:
ShareTweetShareEmail0 SharesMay 8, 2014; The OregonianAs marijuana is legalized either for medical purposes or for recreational use, depending on the state, an infrastructure must be built around it. Some of that infrastructure is limited by its continued categorization as an illegal drug on the federal level. In Colorado, as we reported a few days ago, legislators are trying to get cannabis businesses completely above-board by helping them to access banking services. Operating on a cash-only basis leaves businesses at risk in terms of crime and unable to operate in standard ways, but bankers do not now want their business because of the vagueness of the position of the Feds.According to the Chicago Tribune, “The Obama administration in February issued new law-enforcement guidelines aimed at encouraging banks to start doing business with state-licensed marijuana suppliers, even though such enterprises remain illegal under federal law. The guidance stopped short of promising blanket immunity to banks, and financial industry officials have said they doubted many banks would begin to accept cannabis suppliers as customers without changes in federal law.”So on Wednesday, Colorado approved a co-op banking system, or a nonprofit credit union of sorts, for marijuana-related businesses, although this too will need approval and backing from the Federal Reserve.On another front, insurance companies are not planning on covering the use of cannabis anytime soon. While it is prescribed in 21 states for such ailments as epilepsy, AIDS, cancer, multiple sclerosis, and chronic pain, insurance firms are unwilling to pay for the treatment. Part of the reason has to do with the conflict between state and federal law (for goodness sakes, Feds, just move it along!) and part of their reasoning has to do with the fact that cannabis is not approved by the U.S. Food and Drug Administration. Studies may take years to complete, according to this article, and even those studies are being blockaded by federal law.Currently, marijuana is a Schedule I drug under the Controlled Substances Act and is heavily restricted. Studies would have to gain permission from the FDA, the Public Health Service of the Department of Health and Human Services, the Drug Enforcement Administration, and the National Institute on Drug Abuse.—Ruth McCambridgeShareTweetShareEmail0 Shares